By elucidating the role of specific pathways downstream of the antiviral IFN response that promote secondary bacterial infection, we might identify new host targets with therapeutic potential to combat the poor outcomes observed, particularly in chronic lung disease patients. Here, IFNA1 is linked to bacterial infectious disease.